Treatment of triple negative breast cancer The treatment of triple negative breast cancer is still surgical, if possible, but there is no standardized treatment for the follow-up after surgery. Triple negative breast cancer is a breast cancer with hormone receptor ER(-), PR(-), HER2(-), which is also a breast cancer with higher malignancy, faster appreciation rate, high recurrence rate, low 5-year survival rate, and the majority of women aged 30-40 years old with the disease. The following treatments are available 1. If the primary tumor is less than 0.1 cm without lymph node metastasis, no adjuvant treatment will be given after surgical resection. 2. If the primary tumor is larger than 0.1 cm or less than 0.5 cm, adjuvant chemotherapy will be considered if there are small metastases in regional lymph nodes less than 2 mm. 3. Consider adjuvant chemotherapy if the primary tumor is larger than 0.5 or less than 1 cm and the axillary lymph node metastasis is less than 2 mm. 4. Adjuvant chemotherapy is best if the primary tumor is larger than 1 cm. 5. Positive lymph nodes (1 or more ipsilateral axillary metastases larger than 2 mm) must be treated with adjuvant chemotherapy regardless of tumor size. 6. Chemotherapy can have the following regimens (1) FAC (2) FEC-docetaxel regimen (3) FEC-paclitaxel weekly therapy.